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ABSTRACT 
Purpose : The molecular epidemiology and resistance mechanisms of carbapenem-resistant Pseudomonas 
aeruginosa (CRPA) were determined in hospitals in the countries of the Gulf Cooperation Council (GCC), 
namely, Saudi Arabia, the United Arab Emirates, Oman, Qatar, Bahrain and Kuwait. 
 
Methodology: Isolates were screened for common carbapenem-resistance genes by PCR. Relatedness 
between isolates was assessed using previously described genotyping methods: an informative-single 
nucleotide polymorphism MassARRAY iPLEX assay (iPLEX20SNP) and the enterobacterial repetitive 
intergenic consensus (ERIC)-PCR assay, with selected isolates being subjected to multilocus sequence 
typing (MLST). Ninety-five non-repetitive isolates that were found to be resistant to carbapenems were 
subjected to further investigation. 
 
Results/Key findings: The most prevalent carbapenemase-encoding gene, blaVIM-type, was found in 
37/95 (39%) isolates, while only 1 isolate (from UAE) was found to have blaIMP-type. None of the CRPA 
were found to have blaNDM-type or blaKPC-type. We found a total of 14 sequence type (ST) clusters, with 4 
of these clusters being observed in more than 1 country. Several clusters belonged to the previously 
recognized internationally disseminated high-risk clones ST357, ST235, ST111, ST233 and ST654. We also 
found the less predominant ST316, ST308 and ST823 clones, and novel MLST types (ST2010, ST2011, 
ST2012 and ST2013), in our collection. 
 
Conclusion: Overall our data show that ‘high-risk’ CRPA clones are now detected in the region and 
highlight the need for strategies to limit further spread of such organisms, including enhanced surveillance, 




Pseudomonas aeruginosa is a common opportunistic patho- gen that is associated with hospital-acquired 
infections (HAIs). Multicentre surveys from the USA have shown that P. aeruginosa comprises between 14 
and 21 % of all pathogens causing ventilator-associated pneumonia (VAP) [1–3]. The rate of P. aeruginosa 
association with VAP in Asia can be as high as 42 % [4]. In Saudi Arabia, a prospective cohort of VAP from 
an adult general intensive care unit (ICU) found that 21.7 % were caused by P. aeruginosa [5]. 
 
The success of this pathogen is partially due to the multi- drug-resistant (MDR) phenotype that P. aeruginosa 
demonstrates [6], which more recently has been attributed to the international spread of certain successful 
clones [7–10]. In the Middle East, and the countries of the Cooperation Council for the Arab States of the 
Gulf [GCC; Saudi Arabia, the United Arab Emirates (UAE), Oman, Kuwait, Qatar and Bahrain) in particular, 
the prevalence of carbapenem-resistant P. aeruginosa (CRPA) has increased dramatically over the last 
decade [11]. Al Johani et al. carried out a retrospective analysis of Gram-negative bacilli isolated from the 
adult ICU of King Abdulaziz Medical City in Riyadh, Saudi Arabia. They found a significant decline in the 
susceptibility of P. aeruginosa to carbapenem, from 66 % in 2004 to 26 % in 2009 [12]. CRPA are often 
resistant to other classes of antibiotics [6], which can impede effective treatment, leading to increased 
morbidity and mortality worldwide [6, 13]. 
 
The mechanisms contributing to carbapenem resistance in P. aeruginosa can include alteration of the OprD 
outer-membrane porin, multidrug efflux pumps [6], as well as mobile genetic elements such as plasmid-
encoded carbapenemases. The most notable of these are the plasmid-mediated metallo-b-lactamases 
(MBLs), which are widespread and have been reported around the world [7, 9]. Previous reports on CRPA 
isolates from the GCC states show that carbapenem resistance is most often associated with VIM-type and 
IMP-type MBL enzymes [11, 14, 15]. However, other carbapenemase encoding genes such as blaNDM-type 
[10, 16–21] and blaKPC-type [22–28] have been increasingly reported in P. aeruginosa isolated from 
elsewhere around the world. 
 
Several reports have highlighted the international spread of successful ‘high-risk clones’ of P. aeruginosa. 
Using multilocus sequence typing (MLST), it has been established that P. aeruginosa belonging to sequence 
types 111, 235 and 175 are the most notable high-risk clones. These clones are associated with an MDR 
phenotype, including MBL producers [7, 9, 10, 29]. The GCC region witnesses heavy travel activity as a 
result of the high influx of an international work- force [30] and Hajj [31]. Since travel is known to be a risk 
factor for spreading MDR bacteria [32], this may facilitate the dissemination of MDR high-risk P. aeruginosa 
clones into this region. 
 
In our initial investigations we observed and described an extended-spectrum beta-lactamase (ESBL) PME-
1-producing P. aeruginosa in Qatar [33]. In this study, we aimed to deter- mine the broad molecular 
characteristics of CRPA in the GCC states. To the best of our knowledge, this is the first region- wide 




Between July 2011 and January 2013, P. aeruginosa were collected from seven participating institutes 
across the GCC states [two hospitals in Saudi Arabia, and one hospital each from the UAE, Kuwait, Qatar, 
Oman and Bahrain] (Table 1). No CRPA were contributed by our study hospital in Kuwait. These hospitals 
are part of a region-wide collaborative study on MDR Gram-negative bacilli [33–35]. P. aeruginosa were 
identified and tested for their susceptibility to a panel of antimicrobials using a semi-automated MIC-based 
systems in each clinical microbiology laboratory. Isolates were included on the basis of showing a non-
susceptible phenotype to imipenem (MIC≥8μg ml
-1
), and/or meropenem (MIC≥8μg ml
-1
) using European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints [36]. Only one isolate per patient 
was included, and the isolates originated from a range of clinical specimens. All carbapenem-non-
susceptible isolates were sent to the research laboratory at the University of Queensland Centre for Clinical 
Research (UQCCR), Australia for further investigation. 
 
Antibiotic susceptibility testing 
All non-susceptible isolates referred to the UQCCR underwent confirmatory disk diffusion susceptibility 
testing following the methodology and breakpoints defined by the EUCAST [36] for the following antimicrobial 
agents: ceftazidime, cefepime, piperacillin/tazobactam, imipenem, meropenem, aztreonam, gentamicin, 
amikacin and ciprofloxacin. 
 
PCR for carbapenemase genes and sequencing 
Genomic DNA was extracted using the UltraClean Microbial DNA Isolation kit (Qiagen, Germany) as 
recommended by the manufacturer. Following confirmation of species identification by PAduplex PCR [37], 
each isolate was screened using blaVIM-type PCR, blaIMP-subtype PCR and blaNDM-type-blaKPC-type 
duplex PCR using previously described primer sets [34, 35, 38]. All PCR reactions were carried out using 
GoTaq Green Master Mix (Promega, USA). The resulted PCR products for blaVIM-type and blaIMP-subtype 
were sequenced to identify the variants. 
 
Genotyping of carbapenem-resistant P. aeruginosa 
Each CRPA isolate was subjected to two independent P. aeruginosa genotyping methods comprising an 
iPLEX MassARRAY single nucleotide polymorphism method (iPLEX20SNP) and an enterobacterial repetitive 
intergenic consensus (ERIC) PCR assay. Representative isolates from each combined iPLEX20SNP-ERIC 
PCR cluster, along with four randomly selected singleton isolates, were selected for MLST. 
 
iPLEX20SNP MassARRAY genotyping 
The iPLEX20SNP assay was performed as previously described [39]. Briefly, the method targets 20 
informative SNPs arising from 7 P. aeruginosa housekeeping genes (acsA, aroE, guaA, mutL, nuoD, ppsA 
and trpE), which are distinguished using the Sequenom MassARRAY iPLEX platform and used to predict an 
MLST type. Using these data, the sequence types (STs) were determined by comparing the isolate profiles 
with the 1198 distinct 20 SNP profiles generated from in silico analysis of the 1982 concatenated sequences 
downloaded from the P. aeruginosa MLST database as previously described [39]. 
 
ERIC-PCR 
ERIC-PCR analysis was performed as described previously [40]. In brief, 100 ng of extracted DNA was 
amplified using primers targeting ERIC sequences and thereafter subjected to electrophoresis (80 V) in 1.2% 
agarose for 180min. ERIC-PCR banding patterns were compared using FPQuest cluster analysis software, 
version 4.5 (Bio-Rad Laboratories Pty Ltd, USA). Isolates producing fingerprints related by 100 % [Dice 
coefficient/unweighted pair-group method with arithmetic mean (UPGMA)] were allocated to the same ERIC-
PCR type. Clusters were defined based on >90 % ERIC-PCR banding pattern similarity, as well as the 
predicted MLST profile based on the iPLEX20SNP assay. 
 
MLST 
A total of 19 isolates, selected to represent each cluster (n=15) and some singletons (n=4), from the six 
countries were also subjected to sequencing-based MLST to confirm the precise ST. These isolates 
comprised one isolate each from clusters A, B,C,D,E,F,G,H,I,J,K,M and N, two isolates from the large cluster 
L (Table 2) and four isolates that were identified as singletons (Table 3). The iPLEX20SNP assay typically 
does not distinguish all individual STs, but rather places most iPLEX20SNP types into groups of closely 
related STs [39]. Paired-end libraries of whole genomic DNA of the isolates were prepared via the Nextera 
XT DNA Sample Preparation kit and sequenced by the Illumina HiSeq platform (Illumina, USA). The 100bp 
pair-end reads were de novo assembled using the CLC Genomic Workbench with a minimum contig length 
of 200 bp. One hundred and sixty-seven contigs were assembled with a depth coverage of ca. 100 ︎. The STs 
were determined using in silico MLST analysis [41]. 
 
RESULTS 
Bacterial isolates and carbapenem susceptibility 
A total of 95 non-repetitive isolates that were non-susceptible to imipenem and/or meropenem were referred for further 
susceptibility testing. The numbers of CRPA in each participating hospital were as follows: Saudi Arabia – Riyadh, 43; 
Saudi Arabia – Khobar, 19; United Arab of Emirates, 18; Oman, 1; Qatar, 7; Bahrain, 7 (Table 1). In total, 90/95 isolates 
(95 %) showed resistance to both imipenem and meropenem, whereas 5 isolates were only resistant to 1 of these 
agents, confirming the semi-automated MIC test results provided by the clinical laboratories. Two isolates from Saudi 
Arabia – Khobar were resistant to imipemen, but sensitive to meropenem. Three isolates (one from Saudi Arabia – 
Khobar and two from Saudi Arabia – Riyadh) were resistant to meropenem, but showed a sensitive phenotype to 
imipenem based on the EUCAST criteria. Carbapenem co-resistance for the 95 CRPA isolates was found to be as 
follows: ceftazidime (60 %), aztreonam (39 %), gentamicin (62 %), amikacin (50 %), ciprofloxacin (80 %) and piperacillin/ 
tazobactam (43 %). 
 
Carbapenemase-encoding genes 
Thirty-eight of the 95 (40 %) CRPA isolates showed a positive result for carbapenem-encoding gene PCRs. The carba- 
penem-encoding gene blaVIM-type was encountered most frequently (n=37/95 (39%) isolates) and only one isolate from 
the UAE was found to be carrying the blaIMP-subtype 1 gene. No isolates were positive for blaNDM-type or blaKPC-type. Table 
1 shows the geographical distribution of the VIM-from Saudi Arabia and the UAE. 
 Genotyping and clonality 
iPLEX20SNP analysis 
Complete SNP profiles were obtained for 91/95 (95.8 %) isolates by the iPLEX20SNP assay. Twenty-eight 
different MLST profiles were predicted for them. The three most common predicted MLST profile grouping 
were groups P-15 (n=23 isolates), P-01 (n=15 isolates) and P-05 (n=13 isolates). The other predicted MLST 
profile grouping were less abundant, with some profiles only occurring once (Table 3). The assay also 
predicted isolates with possible novel STs (n=5). Four isolates had incomplete profiles, as one or more SNPs 
could not be characterized by the iPLEX20SNP assay, which was likely caused by sequence variation in the 
primer targets [39]. 
 
ERIC-PCR analysis 
ERIC-PCR analysis combined with predicted MLST profiles identified a total of 14 clusters (clusters A to N, 
comprising 52 isolates; see Table 2) and 43 singletons among the 95 study isolates (Table 3). The largest 
cluster (L) included 17/95 isolates (18%) comprising isolates from the two hospitals in Saudi Arabia and 
Bahrain. Of interest, all cluster L isolates had the same profile, P-15. Cluster A consisted of five Saudi 
isolates (four from Riyadh and one from Khobar). Two clusters (B and K) each consisted of four isolates, 
while clusters G and M had three isolates each. The remaining eight clusters included two isolates each 
(Table 2). 
 
Well-defined clusters by location were observed in clusters C, D, G, I, J, M and N (Table 2), whereas the 
remaining clusters included isolates from two or more locations. Isolates harbouring blaVIM-type were 
scattered throughout the CRPA collection (Tables 2 and 3). All isolates in clusters F, K, L, and M were VIM-
type producers (Table 2). 
 
MLST 
Using MLST, we identified eight different STs (i.e. ST111, ST233, ST235, ST308, ST316, ST357, ST654 and 
ST823) and four novel STs (i.e. ST2010, ST2011, ST2012 and ST2013); all were assigned to the 19 
representative isolates. All STs identified via in silico whole-genome sequence analysis matched with one of 
the predicted STs identified by the iPLEX20SNP assay. Selected isolates representing clusters A, B and C 
were found to be ST357, suggesting that all isolates (n=11) under these clusters may belong to ST357. 
Isolates belonging to cluster D, which consisted of two isolates, were found to be novel sequence type 
ST2010. Cluster E (N=2) had an ST111 isolate. Selected isolates representing clusters F, G and H 
suggested that a total of 12 isolates belonged to ST235. Selected isolates representing clusters I and J, 
which had two isolates each, were found to be ST654 and ST308, respectively. The isolates selected to 
represent cluster K (N=4) were found to be ST823. Two isolates were selected to represent cluster L, which 
consisted of 17 isolates. They were found to be ST233. An ST233 isolate was also found in cluster M, which 
consisted of three isolates. A novel ST2013 was identified in cluster N (Table 2). 
 
DISCUSSION 
Here we describe the molecular characterization of clinical CRPA isolated from selected hospitals in the 
GCC States. We found that VIM type was the most commonly identified carbapenemase in our CRPA 
collection. This finding reflects earlier reports from Saudi Arabia [11, 14, 15] and neigh- bouring Egypt [16, 
42–44]. To the best of our knowledge, our findings are the first to identify VIM-producing P. aeruginosa in the 
UAE, Bahrain and Qatar. 
 
Another commonly found MBL in P. aeruginosa is the IMP type [38, 45]. However, in our collection we only 
found one CRPA carrying blaIMP-1, and it is the first to be reported from the UAE. The rarity of IMP type-
producing P. aeruginosa in the region is consistent with previous investigations [11]. Memish et al. conducted 
a national survey of Gram-negative bacteria in Saudi Arabia, and none of the 40 P. aeruginosa isolated from 
seven Saudi cities produced an IMP-type MBL [14]. However, Al-Agamy et al. only identified only one IMP-7-
producing P. aeruginosa out of 35 CRPA collected at a tertiary hospital in Riyadh, Saudi Arabia [46]. 
 
Despite the emergence and international spread of P. aeruginosa harbouring blaKPC-type and blaNDM-type 
[10, 16, 26], we did not encounter any. Similarly, the survey of MDR P. aeruginosa in Saudi Arabia did not 
find these enzymes [14]. NDM- producing P. aeruginosa have been reported from nearby Egypt [16, 43], and 
among the internationally disseminated high-risk clone ST233 [16], which was also found among our 
collection. We found that approximately 60 % of our CRPA collection were negative for common 
carbapenemase genes. This complements the findings of Memish et al., as 72 % of their Saudi-collected 
isolates were also negative. Carbapenem resistance in P. aeruginosa can arise through various other 
mechanisms, including loss of the carbapenem-specific outer-membrane porin OprD, the overexpression of 
efflux pumps [6], or other carbapenemase enzymes, which we did not test for. 
 
Overall, we found that multiple clusters of clonal CRPA isolates exist in different hospitals across the Gulf 
region. The most notable is the L cluster, which consists of 17 VIM- 2 and VIM-2, 17 or 48 CRPA isolates 
from Saudi Arabia and Bahrain, and belongs to the international high-risk clone ST233. Isolates belonging to 
this cluster – and others – demonstrate very similar resistance phenotypes to multiple antibiotics. We also 
noted that the majority of our CRPA collection belonged to other well-known and internationally disseminated 
high-risk clones, such as ST111, ST235, ST357 and ST654. P. aeruginosa belonging to these STs are 
disseminated in the UK and are associated with MBL production [10]. CRPA isolated from Colombia were 
also found to be associated with ST111 and ST235, and to carry blaVIM-type and blaKPC-type, respectively 
[7]. Our CRPA isolates of interest included the previously described PME-1 ESBL, which also belongs to 
ST654 [33]. These findings are worrying, because the existence of high-risk clones in the GCC might 
facilitate further dissemination of highly resistant P. aeruginosa in local hospitals. 
 
In summary, we analysed clinical CRPA isolates obtained from selected hospitals across the GCC states. 
VIM-type MBL was the most common carbapenemase. We identified clusters belonging to internationally 
disseminated high-risk clones. Knowing the dissemination level of highly resistant CRPA in the region’s 
hospitals may stimulate the enhancement of infection control precautions and the optimization of antibiotic 
stewardship in hospitals, community pharmacies and within agricultural settings. The limitations of our study 
include the fact that only a small number of hospitals contributed isolates – therefore, this is not necessarily a 
representation of the status of CRPA in the region as a whole. It was also not possible to keep track of the 
denominator, and so it was not possible to determine the prevalence of CRPA. Not all of the isolates were 
subjected to sequencing-based MLST, some rather had their MLST types inferred by less discriminatory 
SNP-based profiling. Last, but not least, the intrinsic resistance mechanisms and others carbapenemase 
enzymes were not tested in this study, and the specific VIM and IMP types were not fully ascertained. The 
latter could have been resolved if we had subjected all isolates to WGS, but when this study was conducted 
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